$1.60
+0.12 (+8.11%)
Open$1.51
Previous Close$1.48
Day High$1.62
Day Low$1.50
52W High$9.37
52W Low$4.70
Volume—
Avg Volume590.3K
Market Cap107.78M
P/E Ratio22.41
EPS$0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+575.6% upside
Current
$1.60
$1.60
Target
$10.81
$10.81
$7.63
$10.81 avg
$13.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.16M | 16.05M | 19.98M |
| Net Income | -3,051,276 | -3,462,613 | -3,502,482 |
| Profit Margin | -16.8% | -21.6% | -17.5% |
| EBITDA | -3,542,805 | -3,307,317 | -3,822,507 |
| Free Cash Flow | -2,735,833 | -2,137,974 | -3,204,130 |
| Rev Growth | +3.6% | +0.8% | +4.1% |
| Debt/Equity | 0.80 | 0.67 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |